JP2009544679A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544679A5 JP2009544679A5 JP2009521340A JP2009521340A JP2009544679A5 JP 2009544679 A5 JP2009544679 A5 JP 2009544679A5 JP 2009521340 A JP2009521340 A JP 2009521340A JP 2009521340 A JP2009521340 A JP 2009521340A JP 2009544679 A5 JP2009544679 A5 JP 2009544679A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- cells
- cell
- use according
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102100017234 NFE2L2 Human genes 0.000 claims 3
- 101710031938 NFE2L2 Proteins 0.000 claims 3
- 239000002168 alkylating agent Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 206010059512 Apoptosis Diseases 0.000 claims 2
- -1 C 1 -C 4 (OH) Chemical group 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- 229960003180 Glutathione Drugs 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000002222 downregulating Effects 0.000 claims 2
- 150000004492 retinoid derivatives Chemical class 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 claims 1
- 229960001561 Bleomycin Drugs 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 229960004679 Doxorubicin Drugs 0.000 claims 1
- 101700078985 GSTA2 Proteins 0.000 claims 1
- 102100007616 GSTA2 Human genes 0.000 claims 1
- 101700069532 GSTF2 Proteins 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 229940094937 Thioredoxin Drugs 0.000 claims 1
- 230000003078 antioxidant Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000002194 synthesizing Effects 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 102000002933 thioredoxin family Human genes 0.000 claims 1
- 108060008226 thioredoxin family Proteins 0.000 claims 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 1
Claims (17)
- 治療において使用される医薬品の製造のための、Nrf2遺伝子活性をダウンレギュレートできる薬剤の使用。
- 前記医薬品が異常な細胞増殖に関連する疾患を治療するためのものである、請求項1に記載の使用。
- 前記医薬品が、細胞毒性剤、アルキル化剤、酸化還元サイクル剤、チオール活性化薬、GSH合成の阻害剤、またはアポトーシス誘導剤からなる群から選択される他の薬剤をさらに含むか、あるいは治療される被験体が、さらにUV電離放射線または光力学療法によって治療される、請求項1または2に記載の使用。
- 治療される前記疾患が癌または乾癬である、請求項2または3に記載の使用。
- 前記医薬品が、レチノイドによって感受性を高められた細胞の細胞死を誘導できるさらなる薬剤をさらに含む、請求項5に記載の使用。
- 前記さらなる薬剤が、アルキル化剤または酸化還元サイクル剤などの化学療法剤である、請求項6に記載の使用。
- レチノイドおよび化学療法剤などのNrf2活性をダウンレギュレートできる薬剤を活性成分として含むか、またはそれらから本質的にはなる、医薬組成物。
- 前記化学療法剤がアルキル化剤または酸化還元サイクル化合物である、請求項9に記載の医薬組成物。
- 前記化学療法剤が、シスプラチン、メルファラン、クロラムブチル、ミトロザントロン(mitrozantrone)、BCNU、チステパ(thistepa)、ドキソルビシンまたはブレオマイシンである、請求項10に記載の医薬組成物。
- GSH産生またはチオレドキシン産生を阻害する、BSOなどの酸化還元制御剤をさらに含む、請求項9〜11のいずれか一項に記載の医薬組成物。
- 細胞毒性またはアポトーシスに対して細胞の感受性を高めることに使用される、ARE駆動性遺伝子発現の誘導を直接的または間接的にダウンレギュレートする薬剤についてスクリーニングする方法であって、
a)抗酸化応答を行なうことができる細胞であり、下流に位置するレポーター遺伝子を含み複数の連結されたARE配列によって制御されるAREレポーター遺伝子コンストラクトを含む細胞、をインビトロで提供する工程と;
b)該細胞とスクリーニングされる被検薬剤を接触させる工程と;
c)該薬剤が、被検薬剤が加えられていない細胞に比較して、レポーター遺伝子の誘導を低下できるか、または発現を低下できるかどうかを検出する工程と、
を含むスクリーニング方法。 - 前記被検薬剤がNrf2活性を阻害する能力についてもまた検査される、請求項13に記載の方法。
- 前記細胞がMCF7細胞である、請求項13または14に記載の方法。
- 前記レポーター遺伝子の誘導が活性化剤の追加によって促進される、請求項13〜15のいずれか一項に記載の方法。
- 細胞が、ラットGSTA2および/またはマウスgstal遺伝子からのARE配列の複数の連結したコピーの下流にレポーター遺伝子を含むAREレポーターコンストラクトを含むヒト乳腺MCF7細胞である、ARE駆動性遺伝子発現に対する効果についてのスクリーニング薬剤で使用される細胞。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0614707A GB0614707D0 (en) | 2006-07-25 | 2006-07-25 | Improvements in relation to cancer therapy |
GB0702003A GB0702003D0 (en) | 2007-02-02 | 2007-02-02 | Improvements in relation to cancer therapy |
PCT/GB2007/002833 WO2008012534A2 (en) | 2006-07-25 | 2007-07-25 | Retinoids and small molecules as nrf2 antagonists for use in the treatment of diseases associated with abnormal cell proliferation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009544679A JP2009544679A (ja) | 2009-12-17 |
JP2009544679A5 true JP2009544679A5 (ja) | 2010-09-09 |
Family
ID=38617916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009521340A Pending JP2009544679A (ja) | 2006-07-25 | 2007-07-25 | 異常な細胞増殖に関連する疾患の治療におけるレチノイド及び小分子のNrf2アンタゴニストとしての使用 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20100028460A1 (ja) |
EP (1) | EP2046308A2 (ja) |
JP (1) | JP2009544679A (ja) |
WO (1) | WO2008012534A2 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102264916B (zh) * | 2008-07-25 | 2014-08-20 | 英福康姆株式会社 | 新的癌基因nrf2 |
KR101114544B1 (ko) * | 2009-10-15 | 2012-03-07 | 한국원자력의학원 | Nrf2 활성 억제제 및 그의 용도 |
CN101948805A (zh) * | 2010-09-27 | 2011-01-19 | 扬州大学 | 筛选化学预防剂的双信号转基因细胞传感器及其构建方法 |
RU2766157C2 (ru) * | 2011-06-01 | 2022-02-08 | Интрексон Актобиотикс Н.В. | Система полицистронной экспрессии для бактерий |
CN109890982B (zh) * | 2016-07-08 | 2023-07-07 | 基因泰克公司 | 通过nrf2及其下游目标基因的表达状态和突变状态诊断和治疗癌症的方法 |
US11541116B1 (en) | 2022-01-07 | 2023-01-03 | Kojin Therapeutics, Inc. | Methods and compositions for inducing ferroptosis in vivo |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5527945A (en) * | 1989-02-10 | 1996-06-18 | Basf Aktiengesellschaft | Diphenylheteroalkyl derivatives, the preparation thereof and drugs and cosmetics prepared therefrom |
US5252342A (en) * | 1990-03-05 | 1993-10-12 | The Regents Of The University Of California | Enhancement of anti-neoplastic drug efficacy using EGF |
RU2077885C1 (ru) * | 1992-06-25 | 1997-04-27 | Московский научно-исследовательский онкологический институт им.П.А.Герцена | Противоопухолевое средство для местного лечения злокачественных опухолей |
WO1999006576A1 (en) * | 1997-08-04 | 1999-02-11 | Calydon, Inc. | A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof |
CA2321307A1 (en) * | 1998-02-27 | 1999-09-02 | Venkatachala L. Narayanan | Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs |
US20040228871A1 (en) * | 1999-06-03 | 2004-11-18 | Tayyaba Hasan | Treatment and analysis of proliferative disorders |
US8216777B2 (en) * | 2005-05-26 | 2012-07-10 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of chemoresistant neoplasia |
-
2007
- 2007-07-25 EP EP07789060A patent/EP2046308A2/en not_active Withdrawn
- 2007-07-25 JP JP2009521340A patent/JP2009544679A/ja active Pending
- 2007-07-25 US US12/375,051 patent/US20100028460A1/en not_active Abandoned
- 2007-07-25 WO PCT/GB2007/002833 patent/WO2008012534A2/en active Application Filing
-
2012
- 2012-08-08 US US13/569,853 patent/US20120309087A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mou et al. | Ferroptosis, a new form of cell death: opportunities and challenges in cancer | |
Panieri et al. | Potential applications of NRF2 modulators in cancer therapy | |
Vernier et al. | Estrogen-related receptors are targetable ROS sensors | |
Kumar et al. | Drug targets for cancer treatment: an overview | |
Wu et al. | Isothiocyanates induce oxidative stress and suppress the metastasis potential of human non-small cell lung cancer cells | |
Bao et al. | Inhibiting GLUT-1 expression and PI3K/Akt signaling using apigenin improves the radiosensitivity of laryngeal carcinoma in vivo | |
JP2009544679A5 (ja) | ||
Yang et al. | IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC− | |
Peng et al. | Altered glycolysis results in drug‑resistant in clinical tumor therapy | |
Hu et al. | Hyperoside exhibits anticancer activity in non‑small cell lung cancer cells with T790M mutations by upregulating FoxO1 via CCAT1 | |
Wu et al. | β-phenylethyl isothiocyanate reverses platinum resistance by a GSH-dependent mechanism in cancer cells with epithelial-mesenchymal transition phenotype | |
Leng et al. | Potent neuroprotective effects of novel structural derivatives of valproic acid: potential roles of HDAC inhibition and HSP70 induction | |
Han et al. | Fenofibrate induces G 0/G 1 phase arrest by modulating the PPARα/FoxO1/p27 kip pathway in human glioblastoma cells | |
Mao et al. | A combined modality of carboplatin and photodynamic therapy suppresses epithelial-mesenchymal transition and matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in HEp-2 human laryngeal cancer cells via ROS-mediated inhibition of MEK/ERK signalling pathway | |
Tae et al. | Novel SIRT1 inhibitor 15-deoxy-Δ12, 14-prostaglandin J2 and its derivatives exhibit anticancer activity through apoptotic or autophagic cell death pathways in SKOV3 cells | |
Nasser et al. | Inhibitory effects of Schisandrin B on human prostate cancer cells | |
Zhu et al. | Targeting the NF-E2-related factor 2 pathway: a novel strategy for glioblastoma | |
Sun et al. | Novel 1-alkyl-tryptophan derivatives downregulate IDO1 and IDO2 mRNA expression induced by interferon-gamma in dendritic cells | |
Govindan et al. | Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines | |
Nakajima et al. | Inhibition of the HDAC/Suv39/G9a pathway restores the expression of DNA damage-dependent major histocompatibility complex class I-related chain A and B in cancer cells | |
Alamilla-Presuel et al. | Factors and molecular mechanisms of radiation resistance in cancer cells | |
Zhu et al. | Metabolic shift induced by ω-3 PUFAs and rapamycin lead to cancer cell death | |
Takahashi et al. | Antitumor effect of combination of hyperthermotherapy and 5-aminolevulinic acid (ALA) | |
Calle et al. | Mitochondrial E3 ubiquitin ligase 1 (MUL1) as a novel therapeutic target for diseases associated with mitochondrial dysfunction | |
Shen et al. | Melatonin inhibits bladder tumorigenesis by suppressing PPARγ/ENO1-mediated glycolysis |